Physician profile
Scott D Mcclellan
NPI 1609961853
$6,881.52
in general payments reported to CMS, 2019-2025
24 companies · $1,440 in 2025
The $1,440 reported for 2025 was more than what 80% of Dermatopathology (Dermatology) providers received nationally (typical 2025 total: $251).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $294 · 2020: $213 · 2021: $950 · 2022: $1,408 · 2023: $1,233 · 2024: $1,344 · 2025: $1,440.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,017.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,016.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,006.68 | 2019-2025 | |
| Genzyme Corporation | $837.63 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $735.92 | 2019-2025 | |
| Janssen Biotech, INC. | $581.03 | 2021-2025 | Tremfya |
| Leo Pharma INC. | $469.11 | 2019-2025 | Adbry, Anzupgo |
| Sun Pharmaceutical Industries INC. | $407.70 | 2021-2025 | Ilumya, Winlevi, Absorica Ld |
| Pfizer INC. | $393.31 | 2019-2025 | |
| Ucb, INC. | $242.11 | 2020-2025 | Bimzelx |
| Regeneron Healthcare Solutions, INC. | $237.32 | 2019-2025 | Dupixent |
| Organogenesis INC. | $167.89 | 2023-2024 | Puraply |
| Genentech USA, INC. | $158.89 | 2019-2025 | Xolair, Erivedge |
| E.R. Squibb & Sons, L.L.C. | $99.90 | 2022-2025 | Sotyktu |
| Almirall LLC | $84.42 | 2019-2022 | |
| Organon LLC | $82.44 | 2025 | Vtama |
| Galderma Laboratories, L.P. | $69.55 | 2021-2025 | Nemluvio |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofrontera INC. | $52.00 | 2023-2024 | Ameluz, Xepi, Bf-Rhodoled |
| Lilly USA, LLC | $49.23 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $48.84 | 2020 | |
| Dusa Pharmaceuticals, INC. | $33.83 | 2019 | |
| Incyte Corporation | $31.24 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.19 | 2024-2025 | Spevigo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $24.73 | 2020 | |
| Amgen INC. | $22.77 | 2024 | Otezla |
| Strata Skin Sciences, INC. | $16.79 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Mcclellan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.